Nyrada : Presentation to Meet the CEO Life Sciences Edition

ersonal use only

'Meet the CEO, Life Sciences Edition'

James Bonnar, Nyrada CEO

3 March 2022│Sydney NSW

Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board.

Important Notice & Disclaimer

	This presentation has been prepared by Nyrada Inc (NYR or the Company). It should	Although the Company believes that the expectations reflected in the forward-looking
only			statements are reasonable, none of the Company, its Directors or officers can give, or
	not be considered as an offer or invitation to subscribe for, or purchase any shares in
	NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe	gives, any assurance that the results, performance or achievements expressed or
	for securities in NYR will be entered into on the basis of this presentation or	any	implied by the forward-looking statements contained in this document will actually occur
	i formation, opinions or conclusions expressed in the course of this presentation.			or that the assumptions on which those statements are based are exhaustive or will
	This presentation is not a prospectus, product disclosure document, or other offering	prove to be correct beyond the date of its making.
	d cument under Australian law or under the law of any other jurisdiction. It has been	Readers are cautioned not to place undue reliance on these forward-looking
	prepared for information purposes only. This presentation contains general summary	statements. Except to the extent required by law, the Company has no intention to
use			update or revise forward-looking statements, or to publish prospective financial
	information and does not take into account the investment objectives, financial situation
	and particular needs of an individual investor. It is not a financial product advice, and	information in the future, regardless of whether new information, future events or any
	the Company is not licensed to, and does not provide, financial advice.			other factors affect the information contained in this presentation.
	This presentation may contain forward-looking statements which are identified by words	Readers should make their own independent assessment of the information and take
	s ch as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other	their own independent professional advice in relation to the information and any
	similar words that involve risks and uncertainties. These statements are based on an	proposed action to be taken on the basis of the information. To the maximum extent
	assessment of past and present economic and operating conditions, and on a number	permitted by law, the Company and its professional advisors and their related bodies
ersonal			corporate, affiliates and each of their respective directors, officers, management,
	of assumptions regarding future events and actions that, as at the date of this
	presentation, are expected to take place. Such forward-looking statements do not	employees, advisers and agents and any other person involved in the preparation of
	guarantee of future performance and involve known and unknown risks, uncertainties,	this presentation disclaim all liability and responsibility (including without limitation and
	assumptions and other important factors many of which are beyond the control of the	liability arising from fault or negligence) for any direct or indirect loss or damage which
	Company, its Directors and management.			may arise or be suffered through use of or reliance on anything contained in, or omitted
					from, this presentation. Neither the Company nor its advisors have any responsibility or
					obligation to update this presentation or inform the reader of any matter arising or
					coming to their notice after the date of this presentation document which may affect any
					matter referred to in the presentation.
	NYRADA INC (ASX:NYR)			2			INVESTOR PRESENTATION

Company Overview

only	• Two lead drug development programs with significant
			therapeutic and commercial potential:
			• Cholesterol-Lowering Program
			• Brain Injury Program
use	• Collaborations with world leading institutions, Walter Reed
	Army Institute of Research (WRAIR) and UNSW Sydney
		• Funding secured to complete Phase I studies
		• Commercially focused business model
ersonal	• Experienced Board of Directors with impressive track record in
	biotech
	NYRADA INC (ASX:NYR)			3		INVESTOR PRESENTATION

Nyrada Board of Directors

onlyuse ersonalNYRADA INC (ASX:NYR)

Mr John Moore	Dr IanDixon	Christopher Cox	Mr Peter Marks	Mr Marcus Frampton	Dr Rüdiger Weseloh
Non-Executive	Non-Executive	Non-Executive	Non-Executive	Non-Executive	Non-Executive
Chairman	Director	Director	Director	Director	Director

• Nyrada operates under the direction of a board of international calibre
• Track record in finding and realising the value of biotech companies

4		INVESTOR PRESENTATION

Vision & Strategy

• To improve lives and offer hope through innovation

• Deliver novel treatments for diseases where:

only	• There is unmet clinical need; or
• Current treatments are suboptimal
use

Our strategy is to advance highly optimised drug candidates towards a key value inflection point, such as an efficacy signal, and out-licencethem early, where the risk reward equation is most favourable for Nyrada shareholders

NYRADA INC (ASX:NYR)		5		INVESTOR PRESENTATION
ersonal